The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Leukemia

Volumn 29, Issue 6, 2015, Pages 1336-1343

  Hoffmann, V S ^a   Baccarani, M ^b   Hasford, J ^a   Lindoerfer, D ^a   Burgstaller, S ^c   Sertic, D ^d   Costeas, P ^e   Mayer, J ^f   Indrak, K ^g   Everaus, H ^h   Koskenvesa, P ⁱ   Guilhot, J ^j   Schubert Fritschle, G ^a   Castagnetti, F ^b   Di Raimondo, F ^k   Lejniece, S ^l   Griskevicius, L ^m   Thielen, N ⁿ   Sacha, T ^o   Hellmann, A ^p   Turkina, A G ^q   Zaritskey, A ^r   Bogdanovic, A ^s   Sninska, Z ^t   Zupan, I ^u   Steegmann, J L ^v   Simonsson, B ^w   Clark, R E ^x   Covelli, A ^y   Guidi, G ^y   Hehlmann, R ^z   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Department of Internal Medicine IV Haematology and Oncology Klinikum Wells Grieskirchen   (Austria)

^d KBC Zagreb   (Croatia)

^e Karaiskakio Foundation   (Cyprus)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g PALACKÝ UNIVERSITY   (Czech Republic)

^h TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j POITIERS UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY OF CATANIA   (Italy)

^l RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^m VILNIUS UNIVERSITY   (Lithuania)

ⁿ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^o UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^p MEDICAL UNIVERSITY OF GDANSK   (Poland)

^q NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^r PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^s UNIVERSITY OF BELGRADE   (Serbia)

^t UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^u UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^v HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^w UPPSALA UNIVERSITY   (Sweden)

^x ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^y Novartis Oncology Europe   (Italy)

^z UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMATINIB;

ADULT; AGE; AGED; ARTICLE; AUSTRIA; BASOPHIL; BEHAVIOR DISORDER; BLAST CELL; CANCER INCIDENCE; CANCER PATIENT; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CROATIA; CYPRUS; CZECH REPUBLIC; DIABETES MELLITUS; EOSINOPHIL COUNT; ESTONIA; EUROPE; FEMALE; FINLAND; FRANCE; GERMANY; GROUPS BY AGE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ITALY; LATVIA; LEUKOCYTE COUNT; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; NEUROLOGIC DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLAND; PRIORITY JOURNAL; RUSSIAN FEDERATION; SERBIA; SLOVAKIA; SLOVENIA; SPAIN; SWEDEN; THROMBOCYTE COUNT; UNITED KINGDOM; YOUNG ADULT; COHORT ANALYSIS; FOLLOW UP; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROGNOSIS; REGISTER; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; YOUNG ADULT;

EID: 84930574054     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.73     Document Type: Article

References (36)

1. Hehlmann R, Hochhaus A, Baccarani Mon behalf of the European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007; 370: 342-50.
2. Björkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjöberg J et al. Success story of targeted therapy in chronic myeloid leukemia: A populationbased study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514-2520.
3. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience. Blood 2012; 119: 1981-1987.
4. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-884.
5. O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ et al. Chronic Myelogenous Leukemia, Version 1. 2014. J Natl Compr Canc Netw 2013; 11: 1327-1340.
6. Storey S. Chronic myelogenous leukaemia market. Nat Rev Drug Discov 2009; 8: 447-448.
7. Huang X, Cortes J, Kantarjian H. Estimation of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012; 118: 3123-3127.
8. Experts in Chronic Myeloid Leukemia (Kantarjian H. et al. ). The price of drugs for chronic myeloid leukemia (CML) is a reflection on the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439-4442.
9. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
10. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424-430.
11. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251-2259.
12. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260-2270.
13. Cortes JE, Kim DW, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486-3492.
14. Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010; 28: 2748-2754.
15. Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood 2011; 117: 5591-5599.
16. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363: 2511-2521.
17. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon- in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634-1642.
18. de Lavallade H, Apperley JF, Khorashad J, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358-3363.
19. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013; 121: 4867-4874.
20. Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686-692.
21. Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016-2022.
22. Höglund M, Sandin F, Hellström K, Björeman M, Björkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284-1292.
23. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789-799.
24. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998; 90: 850-858.
25. Waterhouse JAH, Muir CS, Correa P, Powell J (eds). Cancer incidence in five continents. IARC: Lyon, France 1976; 3: 456.
26. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118: 6760-6768.
27. Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis. Blood 2012; 120: 761-767.
28. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of oucomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553-561.
29. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distribution of haematological malignancies in the UK. Hematol Oncol 1997; 15: 173-189.
30. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2112 adult patients in south-east England. Haematologica 2006; 91: 1400-1404.
31. Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23: 602-604.
32. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-3734.
33. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I et al. Rare cancers are not so rare. Eur J Cancer 2011; 47: 2493-2511.
34. Maynadié M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France). Haematologica 2011; 96: 55-61.
35. Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 2013; 98: e95-e97.
36. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER Stat Database: Incidence-SEER 18 Regs Research Data, November 2013 Sub (2000-2011) oKatrina/Rita Population Adjustment4, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission.